Results 21 to 30 of about 2,875 (114)

The Effect of Modified Donanemab Titration on Amyloid-Related Imaging Abnormalities With Edema/Effusions and Amyloid Reduction: 18-Month Results From TRAILBLAZER-ALZ 6

journal of prevention of Alzheimer's disease, The
The TRAILBLAZER-ALZ 6 study (NCT05738486) evaluated the effect of different donanemab dosing regimens on amyloid-related imaging abnormalities with edema/sulcal effusions (ARIA-E).
Stephen Salloway, Scott Andersen, Paula Hauck   +2 more
exaly   +3 more sources

Mini review: Prospective therapeutic targets of Alzheimer's disease

Brain Circulation, 2022
Alzheimer's disease is a neurological condition that causes the disruption of neuronal connections in the human brain. It is progressive and targets about 10% of the United States population over the age of 65.3 to date, there is no cure to the disease ...
RuchiMangal, YuchuanDing
doaj   +1 more source

Donanemab in early symptomatic Alzheimer’s disease: results from the TRAILBLAZER-ALZ 2 long-term extension

The Journal of Prevention of Alzheimer's Disease
Background: Donanemab significantly slowed clinical progression in participants with early symptomatic Alzheimer’s disease (AD) during the 76-week placebo-controlled period of TRAILBLAZER-ALZ 2.
Jennifer A. Zimmer, John R. Sims, Cynthia D. Evans, Emel Serap Monkul Nery, Hong Wang, Alette M. Wessels, Giulia Tronchin, Shoichiro Sato, Lars Lau Raket, Scott W. Andersen, Christophe Sapin, Marie-Ange Paget, Ivelina Gueorguieva, Paul Ardayfio, Rashna Khanna, Dawn A. Brooks, Brandy R. Matthews, Mark A. Mintun   +17 more
doaj   +1 more source

The value of timely treatment with anti‐amyloid therapy for Alzheimer's disease [PDF]

Alzheimers Dement
Abstract INTRODUCTION Anti‐amyloid therapies can slow Alzheimer's disease (AD) progression; diagnostic and treatment delays might reduce their value. METHODS Using dynamic microsimulation, we estimated the gross societal value of anti‐amyloid treatment for Americans with early symptomatic AD. A treatment scenario slowed the rate of clinical progression
Chapel J, Tysinger B, Pourmand H, Goldman D, Aisen P.   +4 more
europepmc   +2 more sources

Lecanemab and Donanemab in Early Alzheimer’s Disease: A Systematic Review of Clinical, Biomarker, and Safety Outcomes

CHRISMED Journal of Health and Research
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia worldwide. Characterized by amyloid-beta (Aβ) accumulation, tau pathology, and cognitive decline, it has long lacked effective disease-modifying ...
Dharmendra Kumar Gupta, Arunima Chaudhuri   +1 more
doaj   +1 more source

Molecular Glue Degraders Enhance CAPRIN1‐Dependent Lysosomal Degradation of APP and Reduce Amyloid β in Alzheimer's Disease

Advanced Science, EarlyView.
A new class of lysosome‐directed molecular glue degraders selectively enhance CAPRIN1–APP interactions, driving APP degradation and reducing amyloid‐β production in human neurons and Alzheimer's disease mouse models. This CAPRIN1‐dependent targeted protein degradation strategy reveals a previously unrecognized therapeutic approach for disrupting the ...
Sunghan Jung, Xu Wang, Bin Liu, Raktim Roy, Nancy Jaiswal, Ratan K. Rai, Yuichiro Takagi, Cen Gao, Lifan Zeng, Ho‐Yin Lo, Reagan K. Wohlford, Ryan K. Higgins, Bruce T. Lamb, Anantha Shekhar, Anita C. Bellail, Chunhai Hao   +15 more
wiley   +1 more source

Regulatory harmonization: Evolution, globalization and future directions

British Journal of Clinical Pharmacology, EarlyView.
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm, Elaine Y. L. Blair, Christine Y. Lu   +2 more
wiley   +1 more source

Research Trends and Mechanistic Insights Into Natural Medicines for Alzheimer's Disease: A Bibliometric Analysis and Narrative Review

Phytotherapy Research, EarlyView.
Research landscape and mechanistic insights into natural medicines for Alzheimer's disease. ABSTRACT Natural medicines have been widely investigated for Alzheimer's disease (AD), but the development of this field and the relationship between bibliometric themes and experimental evidence remain insufficiently characterized.
Maoning Wang, Xiaolian Zhang, Huaxian Yang, Jianhe Zhao, Wentao Wei, Qian Zhao, Wenjia Wang, Yunhui Hu, Jiansong Fang   +8 more
wiley   +1 more source

Neurodegenerative Diseases: Epidemiology, Risk Factors, Classification, Pathophysiology, Clinical Features, Diagnosis, and Therapeutic Strategies

MedComm, Volume 7, Issue 11, November 2026.
Neurodegenerative diseases share convergent risk architectures and pathological mechanisms, yet diverge in selective vulnerability, clinical presentation, and therapeutic responsiveness. This review integrates cross‐disease epidemiology, pathophysiology, diagnosis, and treatment, highlighting the transition from symptomatic care toward biomarker‐guided
Zimeng He, Jingjing Zeng, Guoqing Wang, Yuxin Li, Feng Zhang   +4 more
wiley   +1 more source

Navigating the Challenges of Shared Decision‐Making in Amyloid Immunotherapy for Alzheimer's Disease

European Journal of Neurology, Volume 33, Issue 11, November 2026.
ABSTRACT Background Anti‐amyloid therapies (AATs), such as lecanemab and donanemab, represent a major therapeutic development for early Alzheimer's disease (AD). However, safety risks and uncertainties regarding long‐term effects make treatment decisions complex.
Grâce François, Robin Michalon, Thomas Tannou, Philippe Damier, Sonia Desmoulin, Thibaud Lebouvier   +5 more
wiley   +1 more source